<!--
Homepage version latest-updates

Instruction:

1. Always use three hashtags (###) to start a section title.

2. Please include an anchor link to the detailed latest updates page in each section title.
   You can click the üîó symbol on detailed latest updates page to find out the corresponding anchor link.
   Please follow the existing sections for the correct format.

3. One paragraph description for each section. The paragraph should contain less than ~200 chars.

4. Dated updates should be listed in descending order.

5. For links from covdb.stanford.edu, please remove the leading "https://covdb.stanford.edu".
   For example, "https://covdb.stanford.edu/page/updates/" should be shorten to "/page/updates/".

6. Try not to include plain links such as [https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).
   Please include readable content in the bracket, e.g. [video](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).

7. Please do not delete this instruction.

-->

### [Press Release (Oct 02)](/page/press-release)

[Synairgen plc, Interim results for the six months ended 30 June 2020](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-dev/downloads/press-release/Synairgen20200930.pdf)

### [Press Release (Oct 02)](/page/press-release)

[Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19outpatient setting](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-dev/downloads/press-release/Lilly20200930.pdf)

### [Press Release (Oct 02)](/page/press-release)

[Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms inNon-Hospitalized COVID-19 Patients](https://s3-us-west-2.amazonaws.com/cms.hivdb.org/chiro-dev/downloads/press-release/Regeneron20200930.pdf)

### Study (Oct 01)
Proud PC, Tsitoura D, et int., and Carroll MW. [‚ÄúProphylactic intranasal administration of a TLR2 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.‚Äù](/search/?article=Proud20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.25.309914](https://doi.org/10.1101/2020.09.25.309914).
### Study (Oct 01)
Son J, Huang S, et int., and Ding S. [‚ÄúNitazoxanide and JIB-04 have broad-spectrum antiviral activity and inhibit SARS-CoV-2 replication in cell culture and coronavirus pathogenesis in a pig model.‚Äù](/search/?article=Son20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.24.312165](https://doi.org/10.1101/2020.09.24.312165).
### Study (Oct 01)
Fagre AC, Manhard J, et int., and Schountz T. [‚ÄúA potent SARS-CoV-2 neutralizing human monoclonal antibody that reduces viral burden and disease severity in Syrian hamsters.‚Äù](/search/?article=Fagre20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.25.313601](https://doi.org/10.1101/2020.09.25.313601).
### Study (Oct 01)
Lin C, Li Y, et int., and Chen J. [‚ÄúCeftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction.‚Äù](/search/?article=Lin20) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.14.295956](https://doi.org/10.1101/2020.09.14.295956).
### Study (Oct 01)
Xiao T, Lu J, et int., and Chen B. [‚ÄúA trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro.‚Äù](/search/?article=Xiao20b) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.18.301952](https://doi.org/10.1101/2020.09.18.301952). \[[PubMed32995768](https://www.ncbi.nlm.nih.gov/pubmed/32995768/)\] \[[PMC7523094](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523094/)\]
### Study (Oct 01)
Zhang L, Cao L, et int., and Zhu F. [‚ÄúA proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2.‚Äù](/search/?article=Zhang20f) _bioRxiv_, 2020. [doi.org/10.1101/2020.09.23.309294](https://doi.org/10.1101/2020.09.23.309294).
### Study (Sep 29)
Brunaugh AD, Seo H, et int., and Smyth HD. [‚ÄúBroad-Spectrum, Patient-Adaptable Inhaled Niclosamide-Lysozyme Particles are Efficacious Against Coronaviruses in Lethal Murine Infection Models.‚Äù](/search/?article=Brunaugh20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.09.24.310490](https://doi.org/10.1101/2020.09.24.310490).
### Study (Sep 29)
Curreli F, Victor SMB, et int., and Debnath AK. [‚ÄúStapled peptides based on Human Angiotensin-Converting Enzyme 2 (ACE2) potently inhibit SARS-CoV-2 infection in vitro.‚Äù](/search/?article=Curreli20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.08.25.266437](https://doi.org/10.1101/2020.08.25.266437).
### Study (Sep 25)
Ellen ter B, Dinesh Kumar N, et int., and Smit J. [‚ÄúResveratrol And Pterostilbene Potently Inhibit SARS-CoV-2 Infection In Vitro.‚Äù](/search/?article=Ellen%20ter20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.09.24.285940](https://doi.org/10.1101/2020.09.24.285940).
### Study (Sep 24)
Pereda R, Gonz√°lez D, et int., and Dom√≠nguez RE. [‚ÄúTherapeutic Effectiveness of Interferon-Œ±2b Against COVID-19: The Cuban Experience.‚Äù](/search/?article=Pereda20)¬†_Journal of Interferon & Cytokine Research_,¬†2020.¬†[doi.org/10.1089/jir.2020.0124](https://doi.org/10.1089/jir.2020.0124).¬†\[[PubMed32960147](https://www.ncbi.nlm.nih.gov/pubmed/32960147/)\]
### Study (Sep 23)
Cao L, Goreshnik I, et int., and Baker D. [‚ÄúDe novo design of picomolar SARS-CoV-2 miniprotein inhibitors.‚Äù](/search/?article=Cao20e)¬†_Science_,¬†2020.¬†[doi.org/10.1126/science.abd9909](https://doi.org/10.1126/science.abd9909).¬†\[[PubMed32907861](https://www.ncbi.nlm.nih.gov/pubmed/32907861/)\]
### Study (Sep 15)
Li T, Han X, et int., and Jin A. [‚ÄúA key linear epitope for a potent neutralizing antibody to SARS-CoV-2 S-RBD.‚Äù](/search/?article=Li20e)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.09.11.292631](https://doi.org/10.1101/2020.09.11.292631).
### Study (Sep 14)
Cohen-Dvashi H, Weinstein J, et int., and Diskin R. [‚ÄúCoronacept ‚Äì a potent immunoadhesin against SARS-CoV-2.‚Äù](/search/?article=Cohen-Dvashi20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.08.12.247940](https://doi.org/10.1101/2020.08.12.247940).
### Study (Sep 14)
Glasgow A, Glasgow J, et int., and Wells JA. [‚ÄúEngineered ACE2 receptor traps potently neutralize SARS-CoV-2.‚Äù](/search/?article=Glasgow20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.07.31.231746](https://doi.org/10.1101/2020.07.31.231746).¬†\[[PubMed32766586](https://www.ncbi.nlm.nih.gov/pubmed/32766586/)\]¬†\[[PMC7402043](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402043/)\]
### Study (Sep 14)
Hassan AO, Case JB, et int., and Diamond MS. [‚ÄúA SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies.‚Äù](/search/?article=Hassan20)¬†_Cell_,¬†2020.¬†[doi.org/10.1016/j.cell.2020.06.011](https://doi.org/10.1016/j.cell.2020.06.011).¬†\[[PubMed32553273](https://www.ncbi.nlm.nih.gov/pubmed/32553273/)\]¬†\[[PMC7284254](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284254/)\]
### Study (Sep 14)
Olaleye OA, Kaur M, et int., and Adebusuyi T. [‚ÄúDiscovery of Clioquinol and Analogues as Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 Infection, ACE2 and ACE2 - Spike Protein Interaction In Vitro.‚Äù](/search/?article=Olaleye20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.08.14.250480](https://doi.org/10.1101/2020.08.14.250480).¬†\[[PubMed32817951](https://www.ncbi.nlm.nih.gov/pubmed/32817951/)\]¬†\[[PMC7430586](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430586/)\]
### Study (Sep 14)
de Vries M, Mohamed AS, et int., and Dittmann M. [‚ÄúComparative study of a 3CLpro inhibitor and remdesivir against both major SARS-CoV-2 clades in human airway models.‚Äù](/search/?article=Vries20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.08.28.272880](https://doi.org/10.1101/2020.08.28.272880).¬†\[[PubMed32869028](https://www.ncbi.nlm.nih.gov/pubmed/32869028/)\]¬†\[[PMC7457613](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457613/)\]
### Study (Sep 14)
Zhang Q, Chen CZ, et int., and Ye Y. [‚ÄúHeparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro.‚Äù](/search/?article=Zhang20e)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.07.14.202549](https://doi.org/10.1101/2020.07.14.202549).¬†\[[PubMed32699847](https://www.ncbi.nlm.nih.gov/pubmed/32699847/)\]¬†\[[PMC7373127](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373127/)\]
### Study (Sep 08)
Agarwal A, Mukherjee A, et int., and Abraham P. [‚ÄúConvalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial).‚Äù](/search/?article=Agarwal20)¬†_medRxiv_,¬†2020.¬†[doi.org/10.1101/2020.09.03.20187252](https://doi.org/10.1101/2020.09.03.20187252).
### Study (Sep 08)
Bansal S, Jonsson CB, et int., and C√©sar Vega J. [‚ÄúIota-carrageenan and Xylitol inhibit SARS-CoV-2 in cell culture.‚Äù](/search/?article=Bansal20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.08.19.225854](https://doi.org/10.1101/2020.08.19.225854).
### Study (Sep 08)
Chan KK, Dorosky D, et int., and Procko E. [‚ÄúEngineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.‚Äù](/search/?article=Chan20)¬†_Science_,¬†2020.¬†[doi.org/10.1126/science.abc0870](https://doi.org/10.1126/science.abc0870).¬†\[[PubMed32753553](https://www.ncbi.nlm.nih.gov/pubmed/32753553/)\]
### Study (Sep 08)
Zhu H, Chen CZ, et int., and Huang R. [‚ÄúMining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics.‚Äù](/search/?article=Zhu20e)¬†__,¬†2020.
### Study (Sep 07)
Drayman N, Jones KA, et int., and Tay S. [‚ÄúDrug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro.‚Äù](/search/?article=Drayman20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.08.31.274639](https://doi.org/10.1101/2020.08.31.274639).¬†\[[PubMed32908976](https://www.ncbi.nlm.nih.gov/pubmed/32908976/)\]¬†\[[PMC7480023](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480023/)\]
### Study (Sep 07)
Zhao H, To KKW, et int., and Yuen K. [‚ÄúA broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2.‚Äù](/search/?article=Zhao20)¬†_Nature Communications_,¬†2020.¬†[doi.org/10.1038/s41467-020-17986-9](https://doi.org/10.1038/s41467-020-17986-9).¬†\[[PubMed32843628](https://www.ncbi.nlm.nih.gov/pubmed/32843628/)\]¬†\[[PMC7447754](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447754/)\]
### Study (Sep 07)
Zmudzinski M, Rut W, et int., and Drag M. [‚ÄúEbselen derivatives are very potent dual inhibitors of SARS-CoV-2 proteases - PLpro and Mpro in in vitro studies.‚Äù](/search/?article=Zmudzinski20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.08.30.273979](https://doi.org/10.1101/2020.08.30.273979).
### Study (Sep 04)
Avendano-Sola C, Ramos-Martinez A, et int., and Duarte RF. [‚ÄúConvalescent Plasma for COVID-19: A multicenter, randomized clinical trial.‚Äù](/search/?article=Avendano-Sola20)¬†_medRxiv_,¬†2020.¬†[doi.org/10.1101/2020.08.26.20182444](https://doi.org/10.1101/2020.08.26.20182444).
### Study (Sep 03)
Du S, Cao Y, et int., and Xiao J. [‚ÄúStructures of potent and convergent neutralizing antibodies bound to the SARS-CoV-2 spike unveil a unique epitope responsible for exceptional potency.‚Äù](/search/?article=Du20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.07.09.195263](https://doi.org/10.1101/2020.07.09.195263).
### Study (Sep 03)
Ghahremanpour MM, Tirado-Rives J, et int., and Jorgensen WL. [‚ÄúIdentification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.‚Äù](/search/?article=Ghahremanpour20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.08.28.271957](https://doi.org/10.1101/2020.08.28.271957).¬†\[[PubMed32869018](https://www.ncbi.nlm.nih.gov/pubmed/32869018/)\]¬†\[[PMC7457600](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457600/)\]
### Study (Sep 03)
Gorshkov K, Chen CZ, et int., and Zheng W. [‚ÄúThe SARS-CoV-2 cytopathic effect is blocked with autophagy modulators.‚Äù](/search/?article=Gorshkov20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.05.16.091520](https://doi.org/10.1101/2020.05.16.091520).¬†\[[PubMed32511355](https://www.ncbi.nlm.nih.gov/pubmed/32511355/)\]¬†\[[PMC7259466](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259466/)\]
### Study (Sep 03)
Lang J, Yang N, et int., and Jiang C. [‚ÄúInhibition of SARS Pseudovirus Cell Entry by Lactoferrin Binding to Heparan Sulfate Proteoglycans.‚Äù](/search/?article=Lang11)¬†_PLoS ONE_,¬†2011.¬†[doi.org/10.1371/journal.pone.0023710](https://doi.org/10.1371/journal.pone.0023710).¬†\[[PubMed21887302](https://www.ncbi.nlm.nih.gov/pubmed/21887302/)\]¬†\[[PMC3161750](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161750/)\]
### Study (Sep 03)
Resnick SJ, Iketani S, et int., and Chavez A. [‚ÄúA simplified cell-based assay to identify coronavirus 3CL protease inhibitors.‚Äù](/search/?article=Resnick20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.08.29.272864](https://doi.org/10.1101/2020.08.29.272864).¬†\[[PubMed32869020](https://www.ncbi.nlm.nih.gov/pubmed/32869020/)\]¬†\[[PMC7457602](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457602/)\]
### Study (Sep 02)
Li T, Cai H, et int., and Li D. [‚ÄúA potent synthetic nanobody targets RBD and protects mice from SARS-CoV-2 infection.‚Äù](/search/?article=Li20d)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.06.09.143438](https://doi.org/10.1101/2020.06.09.143438).
### Study (Sep 01)
Bermejo-Jambrina M, Eder J, et int., and Geijtenbeek TBH. [‚ÄúSARS-CoV-2 Infection and Transmission Depends on Heparan Sulfates and Is Blocked by Low Molecular Weight Heparins.‚Äù](/search/?article=Bermejo-Jambrina20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.08.18.255810](https://doi.org/10.1101/2020.08.18.255810).
### Study (Sep 01)
Chen Y, Lear T, et int., and Chen B. [‚ÄúA high throughput screen for TMPRSS2 expression identifies FDA-approved and clinically advanced compounds that can limit SARS-CoV-2 entry.‚Äù](/search/?article=Chen20k)¬†_Research square_,¬†2020.¬†[doi.org/10.21203/rs.3.rs-48659/v1](https://doi.org/10.21203/rs.3.rs-48659/v1).¬†\[[PubMed32818215](https://www.ncbi.nlm.nih.gov/pubmed/32818215/)\]¬†\[[PMC7430593](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430593/)\]
### Study (Sep 01)
Ejemel M, Li Q, et int., and Wang Y. [‚ÄúA cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction.‚Äù](/search/?article=Ejemel20)¬†_Nature Communications_,¬†2020.¬†[doi.org/10.1038/s41467-020-18058-8](https://doi.org/10.1038/s41467-020-18058-8).¬†\[[PubMed32826914](https://www.ncbi.nlm.nih.gov/pubmed/32826914/)\]¬†\[[PMC7442812](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442812/)\]
### Study (Sep 01)
Kreye J, Reincke SM, et int., and Pr√ºss H. [‚ÄúA SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model.‚Äù](/search/?article=Kreye20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.08.15.252320](https://doi.org/10.1101/2020.08.15.252320).¬†\[[PubMed32817952](https://www.ncbi.nlm.nih.gov/pubmed/32817952/)\]¬†\[[PMC7430590](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430590/)\]
### Study (Sep 01)
Noy-Porat T, Makdasi E, et int., and Rosenfeld R. [‚ÄúA panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes.‚Äù](/search/?article=Noy-Porat20)¬†_Nature Communications_,¬†2020.¬†[doi.org/10.1038/s41467-020-18159-4](https://doi.org/10.1038/s41467-020-18159-4).¬†\[[PubMed32855401](https://www.ncbi.nlm.nih.gov/pubmed/32855401/)\]¬†\[[PMC7452893](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452893/)\]
### Study (Sep 01)
Olagnier D, Farahani E, et int., and Holm CK. [‚ÄúIdentification of SARS-CoV2-mediated suppression of NRF2 signaling reveals a potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate.‚Äù](/search/?article=Olagnier20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.07.16.206458](https://doi.org/10.1101/2020.07.16.206458).
### Study (Sep 01)
Schooley RT, Carlin AF, et int., and Hostetler KY. [‚ÄúRethinking Remdesivir: Synthesis of Lipid Prodrugs that Substantially Enhance Anti-Coronavirus Activity.‚Äù](/search/?article=Schooley20)¬†_bioRxiv_,¬†2020.¬†[doi.org/10.1101/2020.08.26.269159](https://doi.org/10.1101/2020.08.26.269159).¬†\[[PubMed32869033](https://www.ncbi.nlm.nih.gov/pubmed/32869033/)\]¬†\[[PMC7457622](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457622/)\]


### [Clinical Trials September 24, 2020](/page/updates/#clinical.trials)
10 clinical trials were added.

### [Preprints => Peer-Reviewed Publications](/page/updates/#preprints.peer-reviewed.publications)

3 published preprints were added since September 16.

### [New spike structure (Sep 24)](/page/updates/#new.spike.structure.sep.24.)
We added a figure [Naturally occurring spike RBD variants and mAb escape mutations](/page/spike-structures/#fig10).

### [New table added (Sep 24)](/page/updates/#new.table.added.sep.24.)
We added a [table of mutation annotations for SARS-CoV-2 Spike gene](/page/mutannot-spike-table/) and data for six monoclonal antibodies.

### [Interface update (Sep 22)](/page/updates/#interface.update.sep.22.)
We now support downloading CSV/Excel files for tables.

### [Editorial (Sep 21)](/page/updates/#a.sars-cov-2.antiviral.therapy.score.card.sep.21.)

Shafer R. ‚ÄúA SARS-CoV-2 antiviral therapy score card‚Äù _Global Health & Medicine_, 2020. [doi.org/10.35772/ghm.2020.01082](https://doi.org/10.35772/ghm.2020.01082).

